322 related articles for article (PubMed ID: 25037253)
21. Genotyping
Jantararoungtong T; Tempark T; Koomdee N; Medhasi S; Sukasem C
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1049-1064. PubMed ID: 34148467
[No Abstract] [Full Text] [Related]
22. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.
Barbaud A; Castagna J; Soria A
Contact Dermatitis; 2022 May; 86(5):344-356. PubMed ID: 35122269
[TBL] [Abstract][Full Text] [Related]
23. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management.
Mockenhaupt M
Semin Cutan Med Surg; 2014 Mar; 33(1):10-6. PubMed ID: 25037254
[TBL] [Abstract][Full Text] [Related]
24. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
Paulmann M; Mockenhaupt M
Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
[TBL] [Abstract][Full Text] [Related]
25. Treatments for Severe Cutaneous Adverse Reactions.
Cho YT; Chu CY
J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
[TBL] [Abstract][Full Text] [Related]
26. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
27. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
28. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.
Cheng CY; Su SC; Chen CH; Chen WL; Deng ST; Chung WH
J Immunol Res; 2014; 2014():565320. PubMed ID: 24901010
[TBL] [Abstract][Full Text] [Related]
29. [The major SCAR syndromes].
Piérard GE; Lesuisse M; Piérard-Franchimont C
Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836
[TBL] [Abstract][Full Text] [Related]
30. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
Hadavand MA; Kaffenberger B; Cartron AM; Trinidad JCL
J Am Acad Dermatol; 2022 Sep; 87(3):632-639. PubMed ID: 32926975
[TBL] [Abstract][Full Text] [Related]
31. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
32. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
33. Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media.
Tasker F; Fleming H; McNeill G; Creamer D; Walsh S
Clin Exp Dermatol; 2019 Dec; 44(8):844-860. PubMed ID: 31162717
[TBL] [Abstract][Full Text] [Related]
34. [Severe delayed drug hypersensitivity reactions].
Maniu CM; Buss G; Feldmeyer L; Spertini F; Ribi C
Rev Med Suisse; 2013 Apr; 9(382):803-4, 806-11. PubMed ID: 23667969
[TBL] [Abstract][Full Text] [Related]
35. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions.
Gomes ESR; Marques ML; Regateiro FS
Curr Pharm Des; 2019; 25(36):3799-3812. PubMed ID: 31694518
[TBL] [Abstract][Full Text] [Related]
37. Making a diagnosis in severe cutaneous drug hypersensitivity reactions.
Ardern-Jones MR; Mockenhaupt M
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):283-293. PubMed ID: 31247634
[TBL] [Abstract][Full Text] [Related]
38. Demographic and laboratory differences seen between acute generalized exanthematous pustulosis and drug reaction with eosinophilia and systemic symptoms: A cross-sectional analysis.
Gallardo MA; Mallela T; Gilkey T; Himed S; Walker TD; Nusbaum KB; Korman A; Trinidad J; Chung C; Kaffenberger BH
J Am Acad Dermatol; 2023 May; 88(5):1142-1145. PubMed ID: 36442643
[No Abstract] [Full Text] [Related]
39. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
40. [DRUG INDUCED EXANTHEMA AND SEVERE CUTANEOUS DRUG REACTIONS].
Bensaïd B; Valeyrie-Allanore L; Lebrun-Vignes B; Nicolas JF
Rev Prat; 2015 Sep; 65(7):981-5. PubMed ID: 26619740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
